Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?

被引：0
|
作者：
Schwartz, Naomi R. M.
Flanagan, Meghan Rose
Babigumira, Joseph B.
Steuten, Lotte Maria Gertruda
Roth, Joshua A.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.6625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6625
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [2] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Tran, Phuong T.
    Diaby, Vakaramoko
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 221 - 221
  • [3] Neratinib in Early-Stage HER2-Positive Breast Cancer
    Cherian, Mathew A.
    Ma, Cynthia X.
    [J]. BREAST DISEASES, 2015, 26 (04): : 285 - 287
  • [4] POTENTIAL COST-EFFECTIVENESS OF NERATINIB FOLLOWING TRASTUZUMAB THERAPY FOR TREATMENT OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
    Schwartz, N. R.
    Steuten, L.
    Babigumira, J. B.
    Roth, J. A.
    [J]. VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [5] Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
    Kourie, Hampig Raphael
    El Rassy, Elie
    Clatot, Florian
    de Azambuja, Evandro
    Lambertini, Matteo
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 3363 - 3372
  • [6] Neratinib for the treatment of HER2-positive early stage breast cancer
    Echavarria, Isabel
    Lopez-Tarruella, Sara
    Marquez-Rodas, Ivan
    Jerez, Yolanda
    Martin, Miguel
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (08) : 669 - 679
  • [7] Spotlight on trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer
    Plosker, Greg L.
    Keam, Susan J.
    [J]. BIODRUGS, 2006, 20 (04) : 259 - 262
  • [8] Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer
    Greg L. Plosker
    Susan J. Keam
    [J]. BioDrugs, 2006, 20 : 259 - 262
  • [9] Neratinib after trastuzumab in patients with HER2-positive breast cancer
    Hasegawa, Takahiro
    Uno, Hajime
    Wei, Lee-Jen
    [J]. LANCET ONCOLOGY, 2016, 17 (05): : E176 - E176
  • [10] Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
    Barcenas, C. H.
    Hurvitz, S. A.
    Di Palma, J. A.
    Bose, R.
    Chien, A. J.
    Iannotti, N.
    Marx, G.
    Brufsky, A.
    Litvak, A.
    Ibrahim, E.
    Alvarez, R. H.
    Ruiz-Borrego, M.
    Chan, N.
    Manalo, Y.
    Kellum, A.
    Trudeau, M.
    Thirlwell, M.
    Saenz, J. Garcia
    Hunt, D.
    Bryce, R.
    McCulloch, L.
    Rugo, H. S.
    Tripathy, D.
    Chan, A.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (09) : 1223 - 1230
12345